Argatroban
Synthetic small-molecule direct thrombin inhibitor — FDA approved 2000 for HIT and PCI. Designed using hirudin structural insights.
Mechanistic Evidence Box
Studied off-label- Page type
- Compound profile
- Evidence type
- Synthetic small-molecule direct thrombin inhibitor — FDA approved 2000 for HIT and PCI. Designed using hirudin structural insights.
- Evidence level
- FDA-cleared regulatory context
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
Argatroban is an FDA-approved synthetic small-molecule direct thrombin inhibitor; it is chemically distinct from hirudin. Its clinical evidence base for HIT and PCI applies only to the drug, not to whole medicinal-leech therapy.
Biological Targets
- → thrombin (Factor IIa)
Key Citations
- Lewis BE et al. (2003), Arch Intern Med · PMID 12912723
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.